Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 6/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765667 | 0.87 | GAA (0.56) | CASP1ELANEL3MBTL1GAA | |
| SCHEMBL30765554 | 0.87 | KDM4E (0.44) | CASP1ELANEAVPR1BL3MBTL1GAA | |
| SCHEMBL30766097 | 0.84 | ASPH (0.49) | CASP1ELANE | |
| SCHEMBL23461187 | 0.82 | KDM4E (0.47) | CASP1ELANE | |
| SCHEMBL30765706 | 0.82 | ELANE (0.47) | ELANELMNA | |
| SCHEMBL5728202 | 0.78 | ELANE (0.54) | CASP1ELANE | |
| SCHEMBL30765857 | 0.77 | BCHE (0.41) | CASP1ELANEAVPR1B | |
| SCHEMBL30766039 | 0.77 | EP300 (0.44) | CASP1ELANE | |
| SCHEMBL30766006 | 0.75 | KDM4E (0.42) | ELANE | |
| SCHEMBL30765482 | 0.75 | KDM4C (0.50) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |